Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial
Authors' conclusion
Control-IQ technology version 1.5, with wider range of weight and TDI input and enhancements for users with high insulin requirements, was safe in individuals with T1D in this study.
Study context
- Population
- Adults with T1D using continuous subcutaneous insulin infusion (CSII) with at least one basal rate >3 units/h; mean age 39.9 years, 41.2% female, diabetes duration 21.8 yearsall completed
- Participants
- 34 adults
- Outcome
- Safety events:
- Severe hypoglycemia
- DKA
- Follow-up
- 13 weeks
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
- There were no severe hypoglycemia or diabetic ketoacidosis (DKA) events
Observational data: associations, not effects.
Further findings
Time in range 70-180 mg/dL · over the 13 weeks
- Time in range 70-180 mg/dL
- 64.8%
Time <70 mg/dL · over the 13 weeks
- Time <70 mg/dL
- 1.0%
Hemoglobin A1c (HbA1c) (central laboratory) · baseline to 13 weeks
- HbA1c at baseline
- 7.69%
- HbA1c at 13 weeks
- 6.87%
- HbA1c change
- −0.82%, P < .001
Safety
Severe hypoglycemia and DKA · 13 weeks
- There were no severe hypoglycemia or DKA events
Original publication
Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial. J Diabetes Sci Technol. Published 5 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →